• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    REPAY Appoints New Chief Financial Officer

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    $MRK
    Real Estate
    Real Estate
    Real Estate
    Real Estate
    Get the next $CNDT alert in real time by email

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025.

    "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO.

    Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT) ("Conduent"). He previously served as Conduent's Global Head of Strategy, Corporate Development and Advisor to CEO. Prior to Conduent, Rob spent seven years at Fiserv, Inc. (NYSE:FI) holding positions as Senior Vice President, General Manager, and CFO across several divisions. Prior to Fiserv, he was the Global Head of FP&A and Investor Relations at Integra Lifesciences, Inc. (NASDAQ:IART). He previously held various finance, accounting, and strategy roles at Firmenich, Inc, Bristol-Myers Squibb Co. (NYSE:NMY), and Merck & Co Inc. (NYSE:MRK). Rob began his career as an auditor for KPMG LLP, and he earned his MBA and bachelor's degree in accounting from Rider University.

    "With Rob's appointment, interim CFO Thomas Sullivan will return to his role as Chief Accounting Officer. We are extremely grateful for Thomas's help in managing the finance organization over the past several months and the entire REPAY team for supporting the company through the CFO transition," said John Morris.

    About REPAY

    REPAY provides integrated payment processing solutions to verticals that have specific transaction processing needs. REPAY's proprietary, integrated payment technology platform reduces the complexity of electronic payments for clients, while enhancing the overall experience for consumers and businesses.

    Forward-Looking Statements

    This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about REPAY's expectations with respect to the announced leadership changes. Such forward-looking statements are based upon the current beliefs and expectations of REPAY's management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond REPAY's control, including, without limitation, the factors described in REPAY's reports filed with the U.S. Securities and Exchange Commission. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements. All information set forth herein speaks only as of the date hereof in the case of information about REPAY or the date of such information in the case of information.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250811411111/en/

    Investor Relations for REPAY:

    [email protected]



    Media Relations for REPAY:

    Kristen Hoyman

    [email protected]

    Get the next $CNDT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNDT
    $FI
    $IART
    $MRK

    CompanyDatePrice TargetRatingAnalyst
    Fiserv Inc.
    $FI
    10/23/2025$128.00Neutral
    Citigroup
    Fiserv Inc.
    $FI
    10/22/2025$130.00Equal Weight
    Wells Fargo
    Fiserv Inc.
    $FI
    10/16/2025Buy → Hold
    Deutsche Bank
    Merck & Company Inc.
    $MRK
    10/13/2025$95.00Neutral
    Citigroup
    Merck & Company Inc.
    $MRK
    9/17/2025$90.00Buy → Hold
    Berenberg
    Fiserv Inc.
    $FI
    7/21/2025Sell → Neutral
    Monness Crespi & Hardt
    Fiserv Inc.
    $FI
    7/17/2025Buy
    Deutsche Bank
    Fiserv Inc.
    $FI
    6/2/2025$181.00Buy
    Truist
    More analyst ratings

    $CNDT
    $FI
    $IART
    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Agadi Harshavardhan V bought $281,000 worth of shares (100,000 units at $2.81) (SEC Form 4)

    4 - CONDUENT Inc (0001677703) (Issuer)

    6/20/25 11:34:48 AM ET
    $CNDT
    Real Estate

    Amendment: President and CEO Skelton Clifford bought $101,700 worth of shares (45,000 units at $2.26), increasing direct ownership by 1% to 4,383,552 units (SEC Form 4)

    4/A - CONDUENT Inc (0001677703) (Issuer)

    5/19/25 9:56:21 PM ET
    $CNDT
    Real Estate

    President Alias Shaler bought $490 worth of shares (118 units at $4.15) (SEC Form 4)

    4 - Repay Holdings Corp (0001720592) (Issuer)

    5/16/25 5:00:19 PM ET
    $RPAY
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & PRESIDENT, INTERNATIONAL Singh Harvinder converted options into 11,965 shares and covered exercise/tax liability with 3,281 shares, increasing direct ownership by 66% to 21,936 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    10/14/25 4:28:29 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Yarkoni Charlotte

    4 - FISERV INC (0000798354) (Issuer)

    10/2/25 4:43:15 PM ET
    $FI
    Real Estate

    SEC Form 4 filed by Director Simons Doyle

    4 - FISERV INC (0000798354) (Issuer)

    10/2/25 4:41:17 PM ET
    $FI
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Fiserv with a new price target

    Citigroup initiated coverage of Fiserv with a rating of Neutral and set a new price target of $128.00

    10/23/25 7:07:21 AM ET
    $FI
    Real Estate

    Wells Fargo initiated coverage on Fiserv with a new price target

    Wells Fargo initiated coverage of Fiserv with a rating of Equal Weight and set a new price target of $130.00

    10/22/25 7:54:16 AM ET
    $FI
    Real Estate

    Fiserv downgraded by Deutsche Bank

    Deutsche Bank downgraded Fiserv from Buy to Hold

    10/16/25 8:19:25 AM ET
    $FI
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    eschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience

    BOSTON, Oct. 23, 2025 /PRNewswire/ -- eschbach is pleased to share that Merck (NYSE:MRK), known as MSD outside the United States and Canada, has selected Shiftconnector to improve how it uses digital tools in manufacturing. By integrating Shiftconnector into its established visual factory framework, Merck is enhancing its ability to deliver real-time, actionable insights across global operations. This implementation supports Merck's continued drive for greater transparency, responsiveness, and efficiency throughout its supply chain. With Shiftconnector now serving as its found

    10/23/25 11:55:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025

    Results from the Phase 3 CORALreef Lipids and HeFH trials of investigational oral PCSK9 inhibitor enlicitide decanoate will be presented for the first time Presentations across hypercholesterolemia and pulmonary arterial hypertension (PAH) underscore Merck's continued commitment to research with the goal of helping address the cardiovascular (CV) epidemic and significant burden of cardio-pulmonary diseases on public health Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from the company's cardio-pulmonary portfolio and pipeline at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, La., from

    10/23/25 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer

    Applications based on Phase 3 KEYNOTE-905 results showing the combination improved event-free survival by 60%, reduced the risk of death by 50% and increased pathologic complete response rates by 48% compared with surgery alone If approved, these would be the first and only perioperative regimens to have improved survival in this patient population Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for two supplemental Biologics License Applications (sBLA) for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination wi

    10/23/25 6:00:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    SEC Filings

    View All

    Conduent Incorporated filed SEC Form 8-K: Leadership Update

    8-K - CONDUENT Inc (0001677703) (Filer)

    10/9/25 4:25:12 PM ET
    $CNDT
    Real Estate

    SEC Form S-8 filed by Repay Holdings Corporation

    S-8 - Repay Holdings Corp (0001720592) (Filer)

    9/26/25 5:20:02 PM ET
    $RPAY
    Real Estate

    Merck & Company Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Merck & Co., Inc. (0000310158) (Filer)

    9/9/25 4:33:09 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer

    PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced the appointment of Dr. Raymond Turner as its new corporate vice president and chief medical officer. Dr. Turner brings more than 20 years of experience in clinical operations, having held senior leadership positions at some of the world's largest global MedTech companies. At Integra, Dr. Turner will lead worldwide medical affairs and clinical development activities including clinical research, clinical trial operations, evidence generation, medical safety and communications. In addition to his role with Integra, Dr. Turner will continue his clinical practice, providi

    9/22/25 8:30:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Conduent Announces Board Leadership Transition

    Harsha V. Agadi Named Chairman, Succeeds Scott Letier Conduent Incorporated (NASDAQ:CNDT), a global technology-driven business solutions and services company, today announced the appointment of Harsha V. Agadi as Chairman of its Board of Directors, effective August 6. He succeeds Scott Letier, who now chairs the Board's Audit Committee. Mr. Agadi joined Conduent's Board in 2025 and previously led its Audit Committee. Mr. Letier has served as a director since 2018 and as Chairman since 2021. These leadership changes are part of the Board's practice of rotating board roles and commitment to strategic governance, as noted in the company's Form 8-K filing on June 25. "We're pleased to wel

    8/6/25 7:45:00 AM ET
    $CNDT
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Financials

    Live finance-specific insights

    View All

    Integra LifeSciences to Host Third Quarter 2025 Financial Results Conference Call on October 30, 2025

    PRINCETON, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release third quarter 2025 financial results on Thursday, October 30, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of th

    10/15/25 8:30:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Fiserv to Release Third Quarter Earnings Results on October 29, 2025

    Fiserv, Inc. (NYSE:FI), a leading global provider of payments and financial services technology solutions, will announce its third quarter financial results before the market opens on Wednesday, October 29, 2025. The company will discuss the results in a live webcast at 7 a.m. CT on October 29. The webcast, along with supplemental financial information, can be accessed on the investor relations section of the Fiserv website at investors.fiserv.com. A replay will be available approximately one hour after the conclusion of the live webcast. About Fiserv Fiserv, Inc. (NYSE:FI), a Fortune 500 company, moves more than money. As a global leader in payments and financial technology, the comp

    10/8/25 2:19:00 PM ET
    $FI
    Real Estate

    Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Oct. 30. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Fr

    10/1/25 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Repay Holdings Corporation

    SC 13G - Repay Holdings Corp (0001720592) (Subject)

    11/14/24 5:17:53 PM ET
    $RPAY
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Conduent Incorporated

    SC 13G/A - CONDUENT Inc (0001677703) (Subject)

    11/14/24 1:28:32 PM ET
    $CNDT
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Fiserv Inc.

    SC 13G/A - FISERV INC (0000798354) (Subject)

    11/14/24 1:22:34 PM ET
    $FI
    Real Estate